[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condbio:mantle-cell-lymphoma:ms4a1-gene":3},{"condition":4,"biomarker":5,"total":6,"trials":7},"Mantle Cell Lymphoma","MS4A1 Gene",6,[8,16,22,28,35,41],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT06054776","Acalabrutinib, Obinutuzumab, and Glofitamab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma",[12],"Phase 2","RECRUITING","2026-08-26T02:16:02.918558Z","2026-05-05T02:43:28.179276Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":20,"content_modified":21},"NCT07257055","Phase 2 Study of BTKi-Rituximab Induction Followed by Glofitamab Consolidation in High Risk Untreated MCL Patients - WINDOW-4 Study",[12],"2026-08-26T02:18:12.612955Z","2026-05-05T02:43:27.813302Z",{"nct_id":23,"title":24,"phases":25,"status":13,"updated_at":26,"content_modified":27},"NCT06263491","Phase II Study of Pirtobrutinib, Rituximab (PR) in Previously Untreated Low and Intermediate Risk MCL (Mantle Cell Lymphoma) Patients",[12],"2026-08-26T02:17:55.355429Z","2026-05-05T02:43:27.392848Z",{"nct_id":29,"title":30,"phases":31,"status":13,"updated_at":33,"content_modified":34},"NCT03571568","A Study of BI-1206 in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell NHL",[32],"Phase 1\u002FPhase 2","2026-08-26T02:18:38.077159Z","2026-05-05T02:43:29.721924Z",{"nct_id":36,"title":37,"phases":38,"status":13,"updated_at":39,"content_modified":40},"NCT06542250","A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R\u002FR B-Cell Malignancies.",[32],"2026-08-26T02:16:14.341106Z","2026-05-05T02:43:29.470752Z",{"nct_id":42,"title":43,"phases":44,"status":13,"updated_at":46,"content_modified":47},"NCT05990465","LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies",[45],"Phase 1","2026-08-26T02:18:14.396999Z","2026-05-05T02:43:27.263994Z"]